SlideShare a Scribd company logo
Drug interactions linked to
transporters.
Introduction
• Drug transporters will effect the nature of the
drug and its effects.
• Uptake – The action of taking up
• Efflux –the flowing out of a particular particle.
• Uptake and efflux transporters determine
plasma and tissue concentrations of a broad
variety of drugs.
Transporters expressed in the
• Small intestine
• Liver
• Kidney
• Blood brain barrier.
• Blood-brain barrier or the maternal-fetal
barrier, have been shown to protect
sensitive tissues from potentially toxic
compounds.
• Inhibition or induction of drug
transporters by coadministered drugs can
alter pharmacokinetics and
pharmacodynamics of the victim drugs.
• Each transporter has a specific pattern of
tissue expression.
classification
• Transporters mediating the
uptake of drugs into cells
• Transporters mediating the
export of drugs or drug
metabolites out of cells.
• Efflux transporters such as P-glycoprotein , the
breast cancer resistance protein , and the
multidrug resistance protein are localized to
the apical membrane of enterocytes [a cell of
the intestinal lining ], thereby limiting
bioavailability of orally administered
substrates.
• After absorption and passage through the
portal vein, drugs reach the basolateral
[ situated below and toward the side ]
membrane of hepatocytes
• Inhibition of these efflux
transporters by concomitantly
administered drugs results in an
increased bioavailability of the
victim drug.
• Whereas induction of these
intestinal efflux transporters
reduces bioavailability of drug
substrates.
• Drug transporters also play a major role for
drug secretion from the proximal tubular cells
of the kidney into urine.
• uptake and efflux transporters for organic
anions are also expressed in the kidney.
Inhibition of these processes by concomitantly
administered drugs leads to a reduced renal
clearance of the victim drug.
A. UPTAKE TRANSPORTERS
Intestinal lumen
• The human OATP family consists of 11 members
grouped into six subfamilies based on their amino
acid sequence similarities.
• From these OATP proteins, to this day four have
been identified as being important for drug
therapy.
• OATP1A2 reported to be expressed in the
intestinal epithelium , the renal epithelium, and
highly expressed in brain capillary endothelial
cells
Transporters expressed in enterocytes of the human intestinal
epithelium. Uptake transporters discussed in this review are colored in
red, export pumps in blue.
Hepatocytes
• OATP1B1 and OATP1B3 , exclusively
expressed in human hepatocytes.
• OATP2B1 the OATP family member being
expressed in almost all tissues.
• OATP1B3 seems to be expressed in colon
polyps, colon cancer and in pancreatic
adenocarcinoma.
• these play an important role for drug
disposition.
• An important drug class with compounds
being transported by OATP1A2, OATP1B1,
OATP1B3, and OATP2B1 are HMG-CoA
reductase inhibitors (statins).
• Pitavastatin has been identified as substrate
for all four OATPs .
• several other drugs have been identified as
substrates for these OATP family members, including
antibiotics, chemotherapeutic agents, antihistaminic
drugs, and diuretics.
• The OAT/OCT Family of
organocation/anion/zwitterion transporters consists
of 23 human members, including the cation
transporters OCTs, the anion transporters OATs.
• The OCT1 protein exhibits a broad tissue distribution
with a high expression in liver and weaker expression
in some other tissues such as spleen and lung.
• Drugs transported by or inhibiting
all three OCTs in vitro include
anesthetic drugs -ketamine and
cocaine, b-blockers -propranolol
antidepressants-Citalopram and
oral antidiabetic drugs -
metformin .
Transporters expressed in human hepatocytes. Uptake transporters
discussed in this review are colored in red, export proteins in blue.
Brain intestinal space
• The anion transporters OAT1 is expressed in
different tissues with the highest expression in
kidney and located there in the basolateral
membrane of proximal tubule cells .
• In addition, mRNA transcripts of OAT1 have been
detected in the brain [cerebellum, hippocampus,
and hypothalamus and the choroid plexus . OAT2
is highly expressed in human liver and to a lower
extent also in the kidney with the same
localization as the OAT1 protein.
Transporters expressed in human brain capillary endothelial
cells. Uptake transporters discussed in this review are colored in red,
export proteins in blue.
B. EFFLUX TRANSPORTERS
• The human multidrug resistance/transporters
of antigen presentation (MDR/TAP) family
consists of 11 different ABC transporters
including the peptide transporters.
• TAP1 and TAP2 are the phospholipid
translocator .
• The drug export pump, and the bile salt
export pump are important for drug
disposition
• P-gp is the most studied export pump
mediating the transport of drugs and drug
conjugates from the intracellular to the
extracellular space.
• It is expressed in several tissues including
intestine, kidney, liver, brain and placenta.
• P-gp is expressed in the apical membrane of
the entire intestine from duodenum to rectum
• P-gp is also important for the blood-brain barrier
as a defense mechanism against the penetration
of toxins and drugs into the central nervous
system.
• P-gp has a very wide substrate spectrum
mediating the export of a variety of drugs from
different drug classes. Substrates include
anticancer drugs (e.g., docetaxel, etoposide,
vincristine), immunosuppressants [e.g.,
cyclosporine (CsA), tacrolimus], antibiotics (e.g.,
macrolides), statins (e.g., atorvastatin, lovastatin),
cardiac drugs (e.g., digoxin, digitoxin), and b-
blockers e.g., carvedilol;
• P-gp is an important determinant of
pharmacokinetics and an important mediator
of transporter-mediated drug-drug
interactions.
• The second MDR1/TAP family member, which
is in particular important for drug side effects
via inhibition of this transporter, is the bile salt
export pump BSEP.
• BSEP shows the highest expression in liver and
is located in the canalicular membrane of
hepatocytes.
• The apically localized export pump MRP2 seems
to be the most important member of this family
for drug disposition.
• MRP2 represents an apically localized export
pump of the MRP family and is highly expressed
in liver, kidney, small intestine , gall bladder, and
placenta.
• The exclusively apical localization is in line with its
role for the excretion of many phase II
metabolites of drugs and endogenous
compounds into bile, urine, and the intestinal
lumen.
• Breast cancer resistance protein (BCRP) is a member of
the ABCG family of ABC transporters. This is so-called
half-size ABC transporter is expressed in different
tissues including intestine, liver, kidney, brain, in
addition in testis and placenta.
• Substrates include antivirals e.g., acyclovir, statins e.g.,
pravastatin and rosuvastatin , anticancer drugs e.g.,
topotecan , antibiotics e.g., ciprofloxacin and ofloxacin,
as well as diclofenac , sulfasalazine , and cimetidine.
• Furthermore, endogenous substances and metabolites
such as vitamin K3 , estrone-3-sulfate,
dehydroepiandrosterone sulfate, and uric acid have
been shown to be transported by BCRP.
• Substances that inhibit BCRP-mediated
export in vitro without being transported
itself include cyclosporine, omeprazole
and pantoprazole,saquinavir, and
tacrolimus.
• MATE1 is expressed in both liver and
kidney, MATE2-K is highly expressed in
kidney and to lower levels also in colon
and testis.
• Thank you

More Related Content

What's hot

Design and evaluation of bioequivalence
Design and evaluation of bioequivalenceDesign and evaluation of bioequivalence
Design and evaluation of bioequivalence
Chandrika Mourya
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
PRAJAKTASAWANT33
 
Drug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactionsDrug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactions
Siva Sivappa
 
In-vivo; Permeability methods
In-vivo; Permeability methodsIn-vivo; Permeability methods
In-vivo; Permeability methods
SaiLakshmi110
 
Invitro invivo insitu method
Invitro invivo insitu methodInvitro invivo insitu method
Invitro invivo insitu method
GURUPRASAD S
 
Drug product performance in vivo biopharmaceutics
Drug product performance in vivo biopharmaceuticsDrug product performance in vivo biopharmaceutics
Drug product performance in vivo biopharmaceutics
Feba Elsa Mathew
 
Properties of GI tract, pH partition hypothesis
Properties of GI tract, pH partition hypothesis Properties of GI tract, pH partition hypothesis
Properties of GI tract, pH partition hypothesis
Naveen Reddy
 
201p
201p201p
Bioavilability and Bioequivalence study designs
Bioavilability and Bioequivalence study designsBioavilability and Bioequivalence study designs
Bioavilability and Bioequivalence study designs
Rajendra Mahajan Mr.Rajmahajan_9990
 
Optimal design & Population mod pyn.pptx
Optimal design & Population mod pyn.pptxOptimal design & Population mod pyn.pptx
Optimal design & Population mod pyn.pptx
PawanDhamala1
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
anumalagundam sreekanth
 
computer aided biopharmaceutical characterization :gastrointestinal absorptio...
computer aided biopharmaceutical characterization :gastrointestinal absorptio...computer aided biopharmaceutical characterization :gastrointestinal absorptio...
computer aided biopharmaceutical characterization :gastrointestinal absorptio...
Affrin Shaik
 
COMPUTERS IN PHARMACEUTICAL DEVELOPMENT
COMPUTERS IN PHARMACEUTICAL DEVELOPMENTCOMPUTERS IN PHARMACEUTICAL DEVELOPMENT
COMPUTERS IN PHARMACEUTICAL DEVELOPMENT
Arunpandiyan59
 
Protein binding interactions
Protein binding interactionsProtein binding interactions
Protein binding interactions
MehulJain143
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Naveen Balaji
 
Problems of variable
Problems of variableProblems of variable
Problems of variable
SAKSHI YADAV
 
Clinical significance of bioequivalence and biowaivers
Clinical significance  of bioequivalence and biowaiversClinical significance  of bioequivalence and biowaivers
Clinical significance of bioequivalence and biowaivers
Nagaraju Ravouru
 
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
ROHIT
 
Drug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding siteDrug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding site
Arabinda Changmai
 
Biowaiver
BiowaiverBiowaiver
Biowaiver
Priyanka Goswami
 

What's hot (20)

Design and evaluation of bioequivalence
Design and evaluation of bioequivalenceDesign and evaluation of bioequivalence
Design and evaluation of bioequivalence
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
 
Drug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactionsDrug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactions
 
In-vivo; Permeability methods
In-vivo; Permeability methodsIn-vivo; Permeability methods
In-vivo; Permeability methods
 
Invitro invivo insitu method
Invitro invivo insitu methodInvitro invivo insitu method
Invitro invivo insitu method
 
Drug product performance in vivo biopharmaceutics
Drug product performance in vivo biopharmaceuticsDrug product performance in vivo biopharmaceutics
Drug product performance in vivo biopharmaceutics
 
Properties of GI tract, pH partition hypothesis
Properties of GI tract, pH partition hypothesis Properties of GI tract, pH partition hypothesis
Properties of GI tract, pH partition hypothesis
 
201p
201p201p
201p
 
Bioavilability and Bioequivalence study designs
Bioavilability and Bioequivalence study designsBioavilability and Bioequivalence study designs
Bioavilability and Bioequivalence study designs
 
Optimal design & Population mod pyn.pptx
Optimal design & Population mod pyn.pptxOptimal design & Population mod pyn.pptx
Optimal design & Population mod pyn.pptx
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
 
computer aided biopharmaceutical characterization :gastrointestinal absorptio...
computer aided biopharmaceutical characterization :gastrointestinal absorptio...computer aided biopharmaceutical characterization :gastrointestinal absorptio...
computer aided biopharmaceutical characterization :gastrointestinal absorptio...
 
COMPUTERS IN PHARMACEUTICAL DEVELOPMENT
COMPUTERS IN PHARMACEUTICAL DEVELOPMENTCOMPUTERS IN PHARMACEUTICAL DEVELOPMENT
COMPUTERS IN PHARMACEUTICAL DEVELOPMENT
 
Protein binding interactions
Protein binding interactionsProtein binding interactions
Protein binding interactions
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
 
Problems of variable
Problems of variableProblems of variable
Problems of variable
 
Clinical significance of bioequivalence and biowaivers
Clinical significance  of bioequivalence and biowaiversClinical significance  of bioequivalence and biowaivers
Clinical significance of bioequivalence and biowaivers
 
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
ICH Q8 GUIDELINES OF QUALITY BY DESIGN(PRODUCT DEVELOPEMENT)
 
Drug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding siteDrug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding site
 
Biowaiver
BiowaiverBiowaiver
Biowaiver
 

Similar to Drug interactions linked to transporters

Intestinal transporters in drug absorption
Intestinal transporters in drug absorptionIntestinal transporters in drug absorption
Intestinal transporters in drug absorptionOmer Mustapha
 
abeer Kinetics 2019 (Pharm 1) - L1.ppt
abeer Kinetics 2019 (Pharm 1) - L1.pptabeer Kinetics 2019 (Pharm 1) - L1.ppt
abeer Kinetics 2019 (Pharm 1) - L1.ppt
NorhanKhaled15
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genome
Akash Agnihotri
 
Transporters
TransportersTransporters
Transporters
Ashishkumar Baheti
 
Drug transport across cell membrane.
Drug transport across cell membrane.Drug transport across cell membrane.
Drug transport across cell membrane.
Dr. Salman H. Rizvi
 
Membrane transporters
Membrane transportersMembrane transporters
Membrane transporters
Darsana Visakh
 
Drug Transporters in Placenta
Drug Transporters in PlacentaDrug Transporters in Placenta
Drug Transporters in Placenta
Parv Dave
 
Pharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptxPharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptx
Dr.Arun Marshalin
 
Membrane transporters and drug response
Membrane transporters and drug responseMembrane transporters and drug response
Membrane transporters and drug response
bhagyamohod90
 
19.los transportistas del tracto intestinal y las técnicas que se aplican par...
19.los transportistas del tracto intestinal y las técnicas que se aplican par...19.los transportistas del tracto intestinal y las técnicas que se aplican par...
19.los transportistas del tracto intestinal y las técnicas que se aplican par...
Ever Alonso Rojas Ch
 
ACTIVE TRANSPORT Pgp,BCRP,NT.pptx
ACTIVE              TRANSPORT            Pgp,BCRP,NT.pptxACTIVE              TRANSPORT            Pgp,BCRP,NT.pptx
ACTIVE TRANSPORT Pgp,BCRP,NT.pptx
SyedaYameen1
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
Priyanka Doshi
 
Genetic variation in drug transporters
Genetic variation in drug transportersGenetic variation in drug transporters
Genetic variation in drug transporters
Deepak Kumar
 
Xenobiotics and cyt p450 by dr rajender
Xenobiotics and cyt p450 by dr rajenderXenobiotics and cyt p450 by dr rajender
Xenobiotics and cyt p450 by dr rajender
rajender kumar arya
 
p-glycoprotein
p-glycoproteinp-glycoprotein
p-glycoprotein
maryam kazemi
 
Drug transporter polymorphism
Drug transporter polymorphismDrug transporter polymorphism
Drug transporter polymorphism
Sreenivasa Reddy Thalla
 
Introduction to drug metabolism case studies for its impacts on drug discover...
Introduction to drug metabolism case studies for its impacts on drug discover...Introduction to drug metabolism case studies for its impacts on drug discover...
Introduction to drug metabolism case studies for its impacts on drug discover...
SAPA-GP
 
CAD note by Ms. Pushpa Sahani
CAD note by Ms. Pushpa SahaniCAD note by Ms. Pushpa Sahani
CAD note by Ms. Pushpa Sahani
KpCreation1
 
Drug Transport and drug target.pptx
Drug Transport and drug target.pptxDrug Transport and drug target.pptx
Drug Transport and drug target.pptx
mrcopyxerox
 

Similar to Drug interactions linked to transporters (20)

Intestinal transporters in drug absorption
Intestinal transporters in drug absorptionIntestinal transporters in drug absorption
Intestinal transporters in drug absorption
 
abeer Kinetics 2019 (Pharm 1) - L1.ppt
abeer Kinetics 2019 (Pharm 1) - L1.pptabeer Kinetics 2019 (Pharm 1) - L1.ppt
abeer Kinetics 2019 (Pharm 1) - L1.ppt
 
Pgp
PgpPgp
Pgp
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genome
 
Transporters
TransportersTransporters
Transporters
 
Drug transport across cell membrane.
Drug transport across cell membrane.Drug transport across cell membrane.
Drug transport across cell membrane.
 
Membrane transporters
Membrane transportersMembrane transporters
Membrane transporters
 
Drug Transporters in Placenta
Drug Transporters in PlacentaDrug Transporters in Placenta
Drug Transporters in Placenta
 
Pharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptxPharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptx
 
Membrane transporters and drug response
Membrane transporters and drug responseMembrane transporters and drug response
Membrane transporters and drug response
 
19.los transportistas del tracto intestinal y las técnicas que se aplican par...
19.los transportistas del tracto intestinal y las técnicas que se aplican par...19.los transportistas del tracto intestinal y las técnicas que se aplican par...
19.los transportistas del tracto intestinal y las técnicas que se aplican par...
 
ACTIVE TRANSPORT Pgp,BCRP,NT.pptx
ACTIVE              TRANSPORT            Pgp,BCRP,NT.pptxACTIVE              TRANSPORT            Pgp,BCRP,NT.pptx
ACTIVE TRANSPORT Pgp,BCRP,NT.pptx
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Genetic variation in drug transporters
Genetic variation in drug transportersGenetic variation in drug transporters
Genetic variation in drug transporters
 
Xenobiotics and cyt p450 by dr rajender
Xenobiotics and cyt p450 by dr rajenderXenobiotics and cyt p450 by dr rajender
Xenobiotics and cyt p450 by dr rajender
 
p-glycoprotein
p-glycoproteinp-glycoprotein
p-glycoprotein
 
Drug transporter polymorphism
Drug transporter polymorphismDrug transporter polymorphism
Drug transporter polymorphism
 
Introduction to drug metabolism case studies for its impacts on drug discover...
Introduction to drug metabolism case studies for its impacts on drug discover...Introduction to drug metabolism case studies for its impacts on drug discover...
Introduction to drug metabolism case studies for its impacts on drug discover...
 
CAD note by Ms. Pushpa Sahani
CAD note by Ms. Pushpa SahaniCAD note by Ms. Pushpa Sahani
CAD note by Ms. Pushpa Sahani
 
Drug Transport and drug target.pptx
Drug Transport and drug target.pptxDrug Transport and drug target.pptx
Drug Transport and drug target.pptx
 

More from gopinathannsriramachandraeduin

What happens to pollutants in the atmosphere
What happens to pollutants in the atmosphereWhat happens to pollutants in the atmosphere
What happens to pollutants in the atmosphere
gopinathannsriramachandraeduin
 
Water pollution
Water pollutionWater pollution
Solid waste management
Solid waste managementSolid waste management
Solid waste management
gopinathannsriramachandraeduin
 
Soil pollution
Soil pollutionSoil pollution
Nuclear hazards
Nuclear hazardsNuclear hazards
Noise pollution
Noise pollutionNoise pollution
Marine pollution
Marine pollutionMarine pollution
Structure of atmosphere
Structure of atmosphereStructure of atmosphere
Structure of atmosphere
gopinathannsriramachandraeduin
 
Five primary pollutants air pollution
Five primary pollutants air pollutionFive primary pollutants air pollution
Five primary pollutants air pollution
gopinathannsriramachandraeduin
 
Types of plagiarism
Types of plagiarismTypes of plagiarism
Types of plagiarism
gopinathannsriramachandraeduin
 
Plagiarism
PlagiarismPlagiarism
Designing the methodology
Designing the methodologyDesigning the methodology
Designing the methodology
gopinathannsriramachandraeduin
 
Experimental design techniques
Experimental design techniquesExperimental design techniques
Experimental design techniques
gopinathannsriramachandraeduin
 
All non parametric test
All non parametric testAll non parametric test
All non parametric test
gopinathannsriramachandraeduin
 
Report writing
Report writingReport writing
Observational study design
Observational study designObservational study design
Observational study design
gopinathannsriramachandraeduin
 
Graphs17052021
Graphs17052021Graphs17052021
Measure of dispersion 10321
Measure of dispersion 10321Measure of dispersion 10321
Measure of dispersion 10321
gopinathannsriramachandraeduin
 

More from gopinathannsriramachandraeduin (20)

Air pollution
Air pollutionAir pollution
Air pollution
 
What happens to pollutants in the atmosphere
What happens to pollutants in the atmosphereWhat happens to pollutants in the atmosphere
What happens to pollutants in the atmosphere
 
Water pollution
Water pollutionWater pollution
Water pollution
 
Solid waste management
Solid waste managementSolid waste management
Solid waste management
 
Soil pollution
Soil pollutionSoil pollution
Soil pollution
 
Nuclear hazards
Nuclear hazardsNuclear hazards
Nuclear hazards
 
Noise pollution
Noise pollutionNoise pollution
Noise pollution
 
Marine pollution
Marine pollutionMarine pollution
Marine pollution
 
Structure of atmosphere
Structure of atmosphereStructure of atmosphere
Structure of atmosphere
 
Five primary pollutants air pollution
Five primary pollutants air pollutionFive primary pollutants air pollution
Five primary pollutants air pollution
 
Air pollution
Air pollutionAir pollution
Air pollution
 
Types of plagiarism
Types of plagiarismTypes of plagiarism
Types of plagiarism
 
Plagiarism
PlagiarismPlagiarism
Plagiarism
 
Designing the methodology
Designing the methodologyDesigning the methodology
Designing the methodology
 
Experimental design techniques
Experimental design techniquesExperimental design techniques
Experimental design techniques
 
All non parametric test
All non parametric testAll non parametric test
All non parametric test
 
Report writing
Report writingReport writing
Report writing
 
Observational study design
Observational study designObservational study design
Observational study design
 
Graphs17052021
Graphs17052021Graphs17052021
Graphs17052021
 
Measure of dispersion 10321
Measure of dispersion 10321Measure of dispersion 10321
Measure of dispersion 10321
 

Recently uploaded

Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 

Recently uploaded (20)

Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 

Drug interactions linked to transporters

  • 1. Drug interactions linked to transporters.
  • 2. Introduction • Drug transporters will effect the nature of the drug and its effects. • Uptake – The action of taking up • Efflux –the flowing out of a particular particle. • Uptake and efflux transporters determine plasma and tissue concentrations of a broad variety of drugs.
  • 3. Transporters expressed in the • Small intestine • Liver • Kidney • Blood brain barrier.
  • 4. • Blood-brain barrier or the maternal-fetal barrier, have been shown to protect sensitive tissues from potentially toxic compounds. • Inhibition or induction of drug transporters by coadministered drugs can alter pharmacokinetics and pharmacodynamics of the victim drugs. • Each transporter has a specific pattern of tissue expression.
  • 5. classification • Transporters mediating the uptake of drugs into cells • Transporters mediating the export of drugs or drug metabolites out of cells.
  • 6. • Efflux transporters such as P-glycoprotein , the breast cancer resistance protein , and the multidrug resistance protein are localized to the apical membrane of enterocytes [a cell of the intestinal lining ], thereby limiting bioavailability of orally administered substrates. • After absorption and passage through the portal vein, drugs reach the basolateral [ situated below and toward the side ] membrane of hepatocytes
  • 7. • Inhibition of these efflux transporters by concomitantly administered drugs results in an increased bioavailability of the victim drug. • Whereas induction of these intestinal efflux transporters reduces bioavailability of drug substrates.
  • 8. • Drug transporters also play a major role for drug secretion from the proximal tubular cells of the kidney into urine. • uptake and efflux transporters for organic anions are also expressed in the kidney. Inhibition of these processes by concomitantly administered drugs leads to a reduced renal clearance of the victim drug.
  • 10. Intestinal lumen • The human OATP family consists of 11 members grouped into six subfamilies based on their amino acid sequence similarities. • From these OATP proteins, to this day four have been identified as being important for drug therapy. • OATP1A2 reported to be expressed in the intestinal epithelium , the renal epithelium, and highly expressed in brain capillary endothelial cells
  • 11. Transporters expressed in enterocytes of the human intestinal epithelium. Uptake transporters discussed in this review are colored in red, export pumps in blue.
  • 12. Hepatocytes • OATP1B1 and OATP1B3 , exclusively expressed in human hepatocytes. • OATP2B1 the OATP family member being expressed in almost all tissues. • OATP1B3 seems to be expressed in colon polyps, colon cancer and in pancreatic adenocarcinoma.
  • 13. • these play an important role for drug disposition. • An important drug class with compounds being transported by OATP1A2, OATP1B1, OATP1B3, and OATP2B1 are HMG-CoA reductase inhibitors (statins). • Pitavastatin has been identified as substrate for all four OATPs .
  • 14. • several other drugs have been identified as substrates for these OATP family members, including antibiotics, chemotherapeutic agents, antihistaminic drugs, and diuretics. • The OAT/OCT Family of organocation/anion/zwitterion transporters consists of 23 human members, including the cation transporters OCTs, the anion transporters OATs. • The OCT1 protein exhibits a broad tissue distribution with a high expression in liver and weaker expression in some other tissues such as spleen and lung.
  • 15. • Drugs transported by or inhibiting all three OCTs in vitro include anesthetic drugs -ketamine and cocaine, b-blockers -propranolol antidepressants-Citalopram and oral antidiabetic drugs - metformin .
  • 16. Transporters expressed in human hepatocytes. Uptake transporters discussed in this review are colored in red, export proteins in blue.
  • 17. Brain intestinal space • The anion transporters OAT1 is expressed in different tissues with the highest expression in kidney and located there in the basolateral membrane of proximal tubule cells . • In addition, mRNA transcripts of OAT1 have been detected in the brain [cerebellum, hippocampus, and hypothalamus and the choroid plexus . OAT2 is highly expressed in human liver and to a lower extent also in the kidney with the same localization as the OAT1 protein.
  • 18. Transporters expressed in human brain capillary endothelial cells. Uptake transporters discussed in this review are colored in red, export proteins in blue.
  • 20. • The human multidrug resistance/transporters of antigen presentation (MDR/TAP) family consists of 11 different ABC transporters including the peptide transporters. • TAP1 and TAP2 are the phospholipid translocator . • The drug export pump, and the bile salt export pump are important for drug disposition
  • 21. • P-gp is the most studied export pump mediating the transport of drugs and drug conjugates from the intracellular to the extracellular space. • It is expressed in several tissues including intestine, kidney, liver, brain and placenta. • P-gp is expressed in the apical membrane of the entire intestine from duodenum to rectum
  • 22. • P-gp is also important for the blood-brain barrier as a defense mechanism against the penetration of toxins and drugs into the central nervous system. • P-gp has a very wide substrate spectrum mediating the export of a variety of drugs from different drug classes. Substrates include anticancer drugs (e.g., docetaxel, etoposide, vincristine), immunosuppressants [e.g., cyclosporine (CsA), tacrolimus], antibiotics (e.g., macrolides), statins (e.g., atorvastatin, lovastatin), cardiac drugs (e.g., digoxin, digitoxin), and b- blockers e.g., carvedilol;
  • 23. • P-gp is an important determinant of pharmacokinetics and an important mediator of transporter-mediated drug-drug interactions. • The second MDR1/TAP family member, which is in particular important for drug side effects via inhibition of this transporter, is the bile salt export pump BSEP. • BSEP shows the highest expression in liver and is located in the canalicular membrane of hepatocytes.
  • 24. • The apically localized export pump MRP2 seems to be the most important member of this family for drug disposition. • MRP2 represents an apically localized export pump of the MRP family and is highly expressed in liver, kidney, small intestine , gall bladder, and placenta. • The exclusively apical localization is in line with its role for the excretion of many phase II metabolites of drugs and endogenous compounds into bile, urine, and the intestinal lumen.
  • 25. • Breast cancer resistance protein (BCRP) is a member of the ABCG family of ABC transporters. This is so-called half-size ABC transporter is expressed in different tissues including intestine, liver, kidney, brain, in addition in testis and placenta. • Substrates include antivirals e.g., acyclovir, statins e.g., pravastatin and rosuvastatin , anticancer drugs e.g., topotecan , antibiotics e.g., ciprofloxacin and ofloxacin, as well as diclofenac , sulfasalazine , and cimetidine. • Furthermore, endogenous substances and metabolites such as vitamin K3 , estrone-3-sulfate, dehydroepiandrosterone sulfate, and uric acid have been shown to be transported by BCRP.
  • 26. • Substances that inhibit BCRP-mediated export in vitro without being transported itself include cyclosporine, omeprazole and pantoprazole,saquinavir, and tacrolimus. • MATE1 is expressed in both liver and kidney, MATE2-K is highly expressed in kidney and to lower levels also in colon and testis.